Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease
Completed
Shanghai Jiao Tong University School of Medicine
Phase 4
2004-06-01
The purpose of this study is to explore the recurrence risk of cardiovascular events in
patients with type 2 diabetes mellitus and coronary heart disease after different
antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized,
parallel control and prospective study
The end point of this study is:
1. follow up 3yr
2. recurrence of cardiovascular event
3. death caused by other reasons such as stroke, uremia, blindness and amputation
Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
Completed
Mylan Pharmaceuticals
Phase 1
2005-06-01
The objective of this study was to investigate the bioequivalence of Mylan's glipizide and
metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets
following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fed
conditions.
Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
Completed
Mylan Pharmaceuticals
Phase 1
2005-06-01
The objective of this study was to investigate the bioequivalence of Mylan's glipizide and
metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets
following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting
conditions.
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Completed
Bristol-Myers Squibb
Phase 3
2008-03-01
This study is being carried out to see if dapagliflozin as an addition to metformin is
effective and safe in treating patients with type 2 diabetes when compared to glipizide
(sulphonylurea) as an addition to metformin treatment.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
